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In our previous study we demonstrated that proteinase PrtP is able to impair bacteriocin
LcnB activity, despite being produced by the same organism and encoded by the
same plasmid. However, precise mechanism of this action, i.e., the exact cleavage site
within LcnB bacteriocin, as well as its effect on antimicrobial activity of the resulting
peptide remained vague. Here we further explored the interplay between these two
proteins and defined, using mass spectrometry, that this unusual hydrolysis indeed
occurs in vivo, between the sixth and seventh amino acid on the N terminus of
LcnB. To address whether the cleaved form of LcnB retains any level of activity, both
recombinant and chemically synthesized variant of truncated LcnB were engineered and
produced, but demonstrated no antimicrobial activity. When LcnB was recombinantly
overexpressed and subjected to PrtP digestion, the change in its antimicrobial activity
was monitored and the degradation products analyzed with reverse-phase high-
pressure liquid chromatography. The results confirmed the inactivity of the truncated
LcnB and additionally corroborated the PrtP cleavage site in LcnB bacteriocin.
In addition, it was demonstrated that, once truncated, LcnB is not able to bind its
receptor and is susceptible to additional hydrolysis. This is the first report on proteolytic
inactivation of bacteriocins inside the same bacterial host.
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INTRODUCTION
Proteolytic system of lactic acid bacteria (LAB) occupied much attention since the 1980s (Law and
Kolstad, 1983) onward, given its importance for efficient bacterial growth and the role it plays
in industrial processes where these bacteria are found in diverse applications. There is a large
amount of data in literature, including some excellent reviews, regarding composition, physiology,
biochemistry, diversity and genetics of proteolytic system in different LAB, especially in lactococci
(Pritchard and Coolbear, 1993; Law and Haandrikman, 1997; Savijoki et al., 2006). Generally,
lactococcal proteolytic system comprises: (a) large cell-envelope proteinase (CEP), responsible for
protein digestion and generation of oligopeptides; (b) multiple oligopeptide transporters, ATP-
binding cassette transporter proteins that mediate the uptake of proteinase-produced peptides; and
(c) intracellular peptidases, enzymes responsible for amino acid release from transported peptides.
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Historically first discovered and the most studied system is the
one present in Lactococcus lactis. Application of its strains has
long tradition in cheese, butter and other dairy production,
branding L. lactis as one of the most exploited bacteria overall.
Consequently, this makes its CEP PrtP one of industrially most
important enzymes. Given that L. lactis is auxotrophic for a
number of amino acids, PrtP represents essential component of
the system providing peptides to the cells and enabling their
rapid growth. Bacteriocins are small ribosomally synthesized
antimicrobial peptides, produced by some bacteria to antagonize
competing ones. Likewise, they have been thoroughly studied,
and large literature data is available on broad array of different
bacteriocins (Diep and Nes, 2002; Cotter et al., 2005, 2013;
Gabrielsen et al., 2014). Given their antimicrobial nature, and the
lack of new and efficient antibiotics, bacteriocins are recognized
as one of the plausible means for combating the antibiotic-
resistant bacteria and their biofilms (Cotter et al., 2013; Mills
et al., 2017; Mathur et al., 2018).
In our previous study (Vukotic et al., 2015), we have
shown that proteinase PrtP alters the bacteriocin LcnB activity
of L. lactis subsp. lactis BGMN1-501. That discovery was
instigated by the analysis of the lcnB gene promoter activity,
during bacterial growth in media with rising concentrations
of casitone. Surprisingly, it was observed that activity of the
lcnB gene promoter was decreasing while the antimicrobial
activity of LcnB was increasing. It was concluded that some
other mechanism is compensating for the silencing of the
lcnB gene transcription. Since the transcription of prtP gene
is also medium dependent, but in opposing manner, we set to
investigate the possible interplay between these two proteins.
Namely, the possibility of LcnB being a substrate for PrtP
was studied, both by making PrtP− mutants and monitoring
their bacteriocin activity, as well as by treating LcnB with
proteinase extract and tracking the same trait. It was shown
that PrtP is capable of impairing bacteriocin LcnB activity,
as its zones of growth inhibition were enlarged in PrtP− mutant
and diminished in the PrtP extracts treatment. Nevertheless,
whether or not cleavage actually happens in vivo and at which
position in LcnB remained to be unambiguously evidenced. More
importantly, the effect of the hydrolysis on the activity of the
single bacteriocin molecule remained open. Hence, the aim of the
present study was to confirm proteolytic cleavage of LcnB by PrtP
in bacterial culture of BGMN1-501, establish the exact position(s)
where the cleavage occurs and determine how this process
reflects on the antimicrobial activity of resulting molecules.
In addition, as it is known that LcnB binds components of
the mannose phosphotransferase system (man-PTS) (Diep et al.,
2007), responsible for glucose uptake, we addressed the activity of
cleaved bacteriocin molecules in this manner.
MATERIALS AND METHODS
Bacterial Strains, Growth
Mediums and Conditions
The bacterial strains and plasmids used in this study are
listed in Table 1. Lactococcus lactis subsp. lactis BGMN1-501
(Kojic et al., 2006) was grown in M17 medium (Oxoid)
supplemented with D-glucose (0.5% w/v) (GM17) at 30◦C.
In addition, chemically defined medium (CDM) was made
according to Miladinov et al. (2001). Escherichia coli DH5α and
ER2523, used for cloning and propagation of constructs, were
grown in Luria-Bertani (LB) broth (Miller, 1972) aerobically
at 37◦C, unless otherwise specified. Agar plates were made by
adding 1.5% (w/v) agar (Torlak Belgrade, Serbia) to the liquid
media. Ampicillin in concentration 100 µg/mL was used for
selection and maintaining of transformants.
Bacteriocin LcnB Purification From
Lactococcus lactis subsp. lactis
BGMN1-501
For the purification and mass spectrometric analysis of the
bacteriocin in Lactococcus lactis subsp. lactis BGMN1-501, the
strain was grown at 30◦C for 16 h in 500 mL of chemically
defined growth medium (CDM)with addition of 0.5% casitone
(Difco Laboratories, Becton Dickinson and Company, Franklin
Lakes, NJ, United States). The bacteriocin was purified following
the protocol of Mirkovic et al. (2016). Briefly, the cells were
removed by centrifugation (4,500 × g for 30 min at 4◦C), while
the supernatant was saturated up to 40% with ammonium sulfate,
and precipitated with stirring for 2 h at 4◦C. The precipitate
was collected by centrifugation (10,000 × g for 30 min at
4◦C) and then dissolved in 5 mL of Milli-Q water containing
0.1% trifluoroacetic acid. The bacteriocin was further purified
using reverse-phase high-performance liquid chromatography
(HPLC). Reverse-phase chromatography of the bacteriocin
sample was performed using an Äkta Purifier 10 system
(GE Healthcare, Uppsala, Sweden) with a Discovery BIO Wide
Pore C5column (10 cm by 4.6 mm; particle size, 5 µm; Supelco,
Bellefonte, PA, United States). The peptide was eluted using an
acetonitrile gradient (0 to 90% with 0.1% trifluoroacetic acid for
10 column volumes). The chromatography was monitored by
measuring absorbance at 215 nm. Twenty six obtained fractions
were dried and dissolved in 10 µL of Milli-Q water, and all
volume was used for antibacterial activity.
Mass Spectrometry Analysis of
Antimicrobial Active Fraction
Mass spectrometry analysis of the active fraction was carried
out using a mass spectrometer coupled with HPLC. The sample
was injected onto a reverse-phase C18 column (RRHT column;
4.6 by 50 mm; particle size, 1.8 µm) coupled with a Zorbax
Eclipse XDB-C18 column installed in a 1200 series HPLC system
(Agilent Technologies). The sample components were separated
using an acetonitrile gradient (5 to 95% with 0.2% formic acid for
10 min and then 95% for 5 min). The mass spectrometer, a 6210
TOF liquid chromatography-mass spectrometry (LC-MS) system
(G1969A; Agilent Technologies, Santa Clara, CA, United States),
was run in positive ESI mode with a capillary voltage of 4,000 V,
a fragmentor voltage of 200 V, and a mass range of m/z 100 to
3,200. Agilent MassHunter Workstation software and Analyst QS
were used for data processing.
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TABLE 1 | The bacterial strains and plasmids used in the study.
Strains Relevant characteristic(s) Source or
References
Lactococcus lactis subsp. lactis
BGMN1-501 Derivate of Lactococcus lactis subsp. lactis BGMN1-5 with pMN80 plasmid, LcnB+, PrtP+, LcnBr Kojic et al., 2006
BGMN1-596 Plasmid free derivate of Lactococcus lactis subsp. lactis BGMN1-5, LcnB−, PrtP−, LcnBs Kojic et al., 2006
Lactococcus lactis subsp. cremoris
NCDO712 PrtP+, Lac+ Gasson, 1983
Escherichia coli
DH5α 3− 880dlacZ1M15 1(lacZYA-argF)U169 recA1 endA1 hsdR17(rk−mk−) supE44thi-1gyrA relA1 Hanahan, 1983
ER2523 fhuA2 [lon] ompT gal sulA11 R(mcr-73::miniTn10–TetS)2 [dcm] R(zgb-210::Tn10–TetS)
endA11(mcrC-mrr)114::IS10
New England Biolabs,
Ltd., United Kingdom
Plasmids
pMAL-c5X pMB1 origin, lacI, malE, bla, Factor Xa cleavage site; 5677 bp New England Biolabs,
Ltd., United Kingdom
pMAL-cX5I pMAL-c5X carrying part of lcnB gene (without leader peptide-encoding DNA sequence) amplified
using LcnB-Fw and LcnB-Rev primers by Vent DNA Polymerase
This study
pMAL-cX5II pMAL-c5X carrying truncated lcnB gene amplified using LcnB∗-Fw and LcnB-Rev primers by Vent
DNA Polymerase
This study
pMN80 80 kbp plasmid carrying prtP and lcnB genes Kojic et al., 2006
LcnB+, lactococcin B producer; PrtP+, proteinase PrtP producer; LcnBr, resistance to LcnB; LcnB−, absence of LcnB production; PrtP−, proteinase PrtP non-producer;
LcnBs, sensitivity to LcnB; Lac+, lactose fermentation ability.
Bacteriocin Activity
Bacteriocin activity of BGMN1-501, as well as of recombinantly
produced bacteriocin was evaluated by an agar-well diffusion test
(Lozo et al., 2004).
The activity of HPLC-obtained fractions and of chemically
synthesized bacteriocin was evaluated by spot-on-lawn assays.
Soft GM17 agar (0.75%, w/v) containing sensitive strain was
overlaid onto thin GM17 agar plates. After soft agar solidified,
10 µL of sample was spotted and plates were incubated at 30◦C
overnight. Clear zones of growth inhibition in the spots were used
as positive signals. Lactococcus lactis subsp. lactis BGMN1-596
was used in all tests as sensitive strain.
Proteinase extract was prepared as following: BGMN1-501
was grown on milk citrate agar plates, collected and re-suspended
in 0.1 mol/L sodium phosphate buffer (NaPi, pH 7), incubated
at room temperature for 30 min, pelleted by centrifugation
and supernatants were collected prior to reactions. In vitro
testing of effect of proteinase extract on bacteriocin activity
was done as previously described (Vukotic et al., 2015),
except that recombinant bacteriocins were used as substrates
in the reactions.
Bacteriocin Competition Assay
The possibility of truncated peptide LcnB∗ to compete with wild
type LcnB for binding to its receptor molecule was tested in
bacteriocin competition assay. Bacteriocin assay was prepared,
as explained above. Before addition of bacteriocin producer,
10 µL of increasing concentrations (62.5–1,000 µg/mL) of
LcnB∗ was added to the wells made in soft agar and left for
30 min at room temperature to be completely adsorbed. After
that, 50 µL of fresh BGMN1-501 culture was added to the
wells, and incubated overnight at 30◦C to produce growth
inhibition zones.
Glucose-Uptake Inhibition Assay
To test whether truncated peptide can interfere with glucose
import, growth of BGMN1-596 in GM17 with added LcnB∗
was monitored. Fresh overnight culture, grown in GM17, was
inoculated at 5% to fresh media, and saturated with increased
concentrations (0–1,000 µg/mL) of chemically synthetized
LcnB∗. As a control, the same inoculum was made in media
without glucose. Bacterial growth was monitored in microtitar
plates by OD measurement at 600 nm at different time points for
6h. The assay was done in triplicate.
DNA Manipulations
Plasmid DNA from lactococci was isolated with the method
described by O’Sullivan and Klaenhammer (1993), while
QIAprep Spin Miniprep Kit was used for plasmid DNA isolation
from E. coli, according to the manufacturer’s recommen-
dations (Qiagen, Hilden, Germany). Vent
R©
DNA Polymerase
(New England Biolabs, Ltd., United Kingdom) was used to
amplify DNA fragments by PCR, using GeneAmp PCR system
2700 thermal cycler (Applied Biosystems, Foster City, CA,
United States). The primers used in PCR for amplification of
the lcnB gene without leader peptide-encoding DNA sequence
and its 18 bp shorter truncated form, the lcnB∗, are listed in
Table 2. The PCR amplified DNA fragments were purified using
QIAquick PCR Purification Kit as described by the manufacturer
(Qiagen). T4 DNA ligase (Agilent Technologies, United States)
was used for DNA ligation of PCR products into pMAL-c5X
vector predigested with XmnI, according to the manufacturer’s
recommendation. Since VentDNA Polymerase was used, blunt
PCR amplicons were obtained, which was suited for ligation with
pMAL-c5X vector, opened with XmnI. Since blunt ligation offers
two possible orientations, ligation mixtures were transformed in
DH5α competent cells, to screen for the appropriate fragment
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TABLE 2 | Sequence of specific primers used in this study.
Primer name Sequence of primer Template Source or References
LcnB-Fw 5′-AGCTTGCAGTATGTTATG-3′ pMN80 plasmid DNA This study
LcnB∗-Fw 5′-AGTGCTGGACCATATACTTGG-3′ pMN80 plasmid DNA This study
LcnB-Rev 5′-TTAGTGGAATGTTTTTCCCC-3′ pMN80 plasmid DNA This study
TABLE 3 | Amino acid sequences of bacteriocin forms used in this study.
Name Sequence of peptide Predicted MW (Da) Source or References
LcnB SLQYVMSAGPYTWYKDTRTGKTICKQTIDTASYTFGVMAEGWGKTFH 5324 Kojic et al., 2006
LcnB∗ SAGPYTWYKDTRTGKTICKQTIDTASYTFGVMAEGWGKTFH 4603 This study
First six amino acids that are cleaved by PrtP proteinase are underlined in the wt LcnB bacteriocin.
orientations. Standard heat-shock transformation was used for
plasmid transfer into E. coli DH5α (Hanahan, 1983).
The presence of cloned fragments in pMAL-c5X was
determined using NcoI/SacI digestion, while the orientation was
determined by sequencing using Macrogen Sequencing Service
(Macrogen, Netherlands). All digestions with restriction enzymes
were conducted according to the supplier’s instructions (Thermo
Fisher Scientific).
Chemical Synthesis of Bacteriocin
LcnB∗, the truncated form of bacteriocin LcnB lacking first six
amino acids (Table 3), was synthesized by Biomatik Corporation
(Cambridge, Canada).
Recombinant LcnB and LcnB∗
Overexpression in E. coli ER2523
and Purification
Plasmid constructs with appropriate fragment orientation,
designated as pMAL-cX5I (carrying complete coding sequence
for LcnB) and pMAL-cX5II (truncated for six amino acids at
N terminus) were transformed into E. coli ER2523 competent
cells (New England Biolabs). Transformants were selected
on LA Petri dishes containing ampicillin (100 µg/mL) at
37◦C. Expression of recombinant peptides was carried out
at 22◦C by induction with 0.1 mmol/L isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 2 h. Purification (cell lysis,
affinity chromatography, cleavage of fusion protein with
Xa protease) was performed according to manufacturer’s
instructions (pMAL Protein Fusion & Purification System; New
England Biolabs, Ltd., United Kingdom). Purified recombinant
LcnB and LcnB∗ bacteriocins were stored at−20◦C in CM buffer
(20 mmol/L Tris–HCl pH 7.4, 200 mmol/L NaCl, 1 mmol/L
EDTA, 1 mmol/L DTT) containing 50% glycerol.
SDS-PAGE
Recombinant peptides were analyzed by SDS-PAGE, as previ-
ously described (Vukotic et al., 2015).
HPLC of Recombinant Peptides
Both recombinant peptides and the reaction mixtures of
LcnB and PrtP were analyzed using the same reverse-phase
chromatography as used for bacteriocin purification (see Section
“Bacteriocin LcnB Purification From Lactococcus lactis subsp.
lactis BGMN1-501”).
Bioinformatic Analysis of LcnB
Bioinformatic analysis of LcnB was carried out using JPred4, the
latest version of JPred, one of the most accurate protein secondary
structure prediction servers (Drozdetskiy et al., 2015). This neural
network-based server was used to predict propensity of each
amino acid residue in given sequence to form certain type of
secondary structure.
RESULTS
Purification and Mass Spectrometric
Analysis of Bacteriocin LcnB
BGMN1-501 was successfully cultivated in chemically defined
medium and tested positively for bacteriocin activity (data
not shown). The proteins present in the supernatant were
precipitated by ammonium sulfate precipitation at 40%
saturation, dialyzed and separated by RP-HPLC. Twenty-
six obtained fractions were concentrated and tested for
antimicrobial activity using spot-on-lawn method. The active
fraction (fraction 24, Figure 1) was analyzed by ESI-TOF MS
and the molecular mass of the present peptides was determined.
FIGURE 1 | Testing of HPLC-purified fractions of MN1-501 proteins from cell
free supernatant for bacteriocin activity. L. lactis subsp. lactis BGMN1-596
was used as sensitive strain.
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FIGURE 2 | Mass spectrometry results of: (A) LcnB and (B) truncated peptide (LcnB∗) present in HPLC-derived active fraction 24.
Beside the [M + 2H]2+peak corresponding to predicted
molecular mass of wild type LcnB/ (Figure 2A), additional
peptide was detected (Figure 2B). The mass analysis showed
that the recorded molecular ion of this peptide was m/z 1534.8
([M+ 3H]3+), which indicated the molecular mass of 4601.4 Da.
Based on LcnB amino acid sequence analysis, the detected
peptide corresponded perfectly to theoretical LcnB truncated of
the first six amino acids of the mature peptide.
Truncated Form of LcnB (LcnB∗)
Is Not Active
When the presence of two peptides in the active fraction was
established, we set out to determine and possibly compare the
activity of both. We ordered chemically synthesized truncated
form of LcnB, shortened for six amino acids from N terminus,
from Biomatik (Cambridge, Canada) and found it inactive on
sensitive strain BGMN1-596, even in very high concentrations
such as 1 mg/mL. However, since the manufacturer could not
produce the wild type peptide, we decided to produce both
peptides by means of genetic engineering. LcnB and LcnB∗
were produced as their mature peptide forms using pMAL
protein fusion and expression system. Briefly, using plasmid
pMN80 as template, both lcnB without leader peptide-encoding
DNA sequence and its 18 bp shorter form were amplified
with PCR and cloned in pMAL-c5X to be in-frame with
maltose binding protein (MBP), and transformed into ER2523
strain for overexpression. The transformants were selected and
propagated at 22◦C for overexpression and purification, because
the induction of expression under normal conditions (37◦C)
resulted in insoluble proteins of interest. Similar results were also
observed by other researchers (Chung et al., 2011; Miljkovic et al.,
2018). Overview of the cloning and expression process is given in
Supplementary Figure S1.
When tested in spot-on-lawn bacteriocin activity assay,
LcnB demonstrated strong antimicrobial activity, dependent on
applied concentration. However, LcnB∗ proved to be inactive
regardless of the concentration applied (Figure 3).
In vitro PrtP Digestion of Recombinant
LcnB Yields LcnB∗
In order to confirm the premises put forward by previous results,
recombinant LcnB was subjected to PrtP hydrolysis in vitro
and monitored for activity and peptide generation. As expected,
PrtP extract reduced the bacteriocin activity of LcnB after 3 h
of incubation as zones of growth inhibition diminished, both
in spot-on-lawn and agar-well test (Figure 4). However, some
residual activity remained, which had also been demonstrated
in our previous work on wild type bacteriocin, isolated from
BGMN1-501. After 20 h of incubation with proteinase PrtP, no
activity could be detected (data not shown).
In order to investigate the pattern and kinetics of PrtP
hydrolysis of LcnB, the components of digestion mixture were
separated using reverse-phase HPLC after 3 and 20 h of digestion.
In addition, recombinant LcnB as starting substrate and LcnB∗
as potential product were also loaded on the same column and
separated under the same conditions, to establish the adequate
controls (Figure 5). As can be seen on the figure, retention
volumes of controls in given conditions were 11.9 mL for wt LcnB
(Figure 5A), and 12.2 mL for LcnB∗ (Figure 5D). As for the 3 h
hydrolysis (B), it can be seen that another peak emerged in the
FIGURE 3 | Antimicrobial activity of recombinant LcnB (A) and LcnB∗ (B).
Growing concentrations (50–500 µg/mL) of each bacteriocin were spotted on
lawn of sensitive BGMN1-596 cells. LcnB activity is concentration dependent
while LcnB∗ does not possess antimicrobial activity.
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FIGURE 4 | Antimicrobial activity of recombinant LcnB before and after 3 h
incubation with PrtP proteinase in agar-well diffusion (1–2), and in
spot-on-lawn (3–4) assays.
close vicinity of the original one, perfectly corresponding to the
peak generated by LcnB∗. In addition, further degradation can be
noted in the background. With the prolonged time of hydrolysis
(Figure 5C), it is clear that the amount of original substrate LcnB
is drastically reduced, however, the same is happening to the
LcnB∗ peptide – suggesting that apart from the specific digestion
occurring at sixth amino acid in the peptide, hydrolysis extends
to other peptide bonds forming a background signal, notable on
the chromatogram.
LcnB∗ Does Not Interact With
LcnB Receptor
The presence of LcnB∗ in the highest concentration did not
alter bacterial growth, given that bacteria grew evenly well in the
presence as in the absence of LcnB∗ (Supplementary Figure S2).
In addition, pretreatment of sensitive MN1-596 cells with high
concentrations of LcnB∗ did not influence the latter bacteriocin
activity of wild type molecule on the same cells (Supplementary
Figure S3). Taken together, these results testify that truncated
molecule does not bind nor block the receptor for LcnB on the
surface of sensitive cells.
Bioinformatic Analysis Predicts Loss of
Secondary Structure in LcnB∗
JPred4 analysis of amino acid sequence of wild type bacteriocin
predicted three β-strands and one α-helix (Figure 6). The first
β-strand comprises four residues from the first six amino acids
(QYVM) of the peptide, implying that this part of the peptide has
an important function in secondary structure formation.
DISCUSSION
In our previous paper, we described the medium dependent
regulation of bacteriocin LcnB activity in BGMN1-501, and
gave the first insights into interaction between proteinase PrtP
and LcnB bacteriocin. Through the generation and analyses of
single-gene knockouts it was shown that bacteriocin activity
is negatively regulated by PrtP, which is on the other hand
FIGURE 5 | RP-HPLC of recombinant LcnB (A), recombinant LcnB
hydrolyzed with PrtP for 3 h (B), recombinant LcnB hydrolyzed with PrtP for
20 h (C) and recombinant LcnB∗ (D). Details are given in the text.
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FIGURE 6 | JPred4 prediction of secondary structure formation in LcnB. Yellow arrows: β-strands; Red cylinder: α-helix.
negatively regulated by the peptide concentration in the growth
medium. Finally, it was demonstrated that PrtP impaired LcnB
activity in vitro. However, an in vivo study was needed to confirm
whether this unusual hydrolysis actually occurs and consequently
to determine at which peptide bond, as well as its severity to
the function of bacteriocin. This was also interesting from the
point of bacteriocin mode of action, given that structure and
receptor-biding domain are still undefined for this bacteriocin.
To approach this problem, we decided to purify and detect
the bacteriocin present in the overnight culture of BGMN1-501,
using mass spectrometry. The rationale for this was the following:
if the hydrolysis of LcnB does not occur, a peak of adequate
bacteriocin mass would be detected in the active fraction; if,
however, the hydrolysis of LcnB indeed occurs, we would either
detect one peptide of smaller mass or two peptides of different
masses inside the active fraction, or two active fractions each
carrying an active peptide.
To determine the form(s) of LcnB present in BGMN1-501
culture, the strain was grown in chemically defined minimal
medium, supplemented with 0.5% casitone. This was done
for two reasons: (i) to grow bacteria in conditions favoring
PrtP expression and hence putative bacteriocin digestion,
and (ii) to reduce the presence and number of molecules
which could interfere with subsequent manipulations, i.e.,
chromatographic separation and detection of molecules of
interest. Mass spectrometry revealed two peptides present in
active fraction, one corresponding to theoretical bacteriocin
LcnB, and the other of smaller mass. The peptide sequence
analysis revealed that the obtained 721 Da difference between
the two detected peptides corresponded perfectly to theoretical
mass of first six amino acids in LcnB. This strongly indicated that
the additional peptide present in the active fraction is indeed the
truncated form of LcnB.
This finding confirmed that LcnB actually gets hydrolyzed
during bacterial growth. However, since both peptides were
detected in the active fraction, the activity of the truncated form,
named LcnB∗, could not be determined. To define and compare
the activity of both forms of bacteriocin, they were produced
with cloning work using pMAL expression system. Once purified,
both peptides were tested for antimicrobial activity, but growth
inhibition zone was produced only by wild type peptide LcnB,
while LcnB∗ expressed no activity. This was also the case when
chemically synthesized truncated bacteriocin was applied.
Chromatographic analysis of pattern and kinetics of PrtP-
LcnB digestion, paralleled with bacteriocin activity assays, gave
the final confirmation of our work. The results demonstrated that
once exposed to PrtP, LcnB gets converted to LcnB∗ and loses
activity. The cleavage site was confirmed to be between sixth
and seventh amino acid in the peptide, as the retention volume
of the peak generated in hydrolysis matched the peak generated
by recombinant LcnB∗. It also became evident that additional
hydrolysis occurs with time. Therefore, it can be concluded that
the preferred site for PrtP action is methionine-serine bond at the
N terminus of LcnB, however, peptides liberated by this action
may be further hydrolyzed with time.
Finally, the deleterious effect of the missing amino acids
on structuring the bacteriocin molecule was ascertained with
bioinformatic analysis of LcnB. Given that detailed 3D structure
of this bacteriocins is yet undetermined, the influence of given
six amino acids removal on the final protein structure is hard
to predict. However, secondary structure prediction suggested
that these six amino acids are involved in β-sheet formation.
Given that this β-sheet is predicted to be rather small, consisting
of three strands and only 12 amino acids, it is highly probable
that deletion of first β-strand, induced by PrtP, destabilizes the
structure completely, leading to denaturation of this β-sheet.
The loss of antimicrobial activity after here described deletion
by PrtP proteinase, suggests that LcnB receptor binding domain
is functionally disrupted without first six amino acids and cannot
interact with the receptor molecule. This conclusion is supported
with results obtained in glucose-uptake inhibition experiment
where it was demonstrated that bacterial growth is not altered
in the presence of LcnB∗ meaning that truncated peptide
does not interfere with glucose import by man-PTS, which is
bacteriocin target molecule. Likewise, bacteriocin competition
assay confirmed the lack of competition between LcnB∗ and
LcnB for the receptor. The experiment was set according to
Ovchinnikov et al. (2014) who determined the receptor binding
domain of another bacteriocin, LsbB, by producing an array of
different bacteriocin-derived peptides and tracking the blocking
activity of each peptide in microtitar plate assay. We used the
same logic in bacteriocin competition assay, in which we pre-
incubated sensitive cells with LcnB∗ to allow its attachment to the
receptor molecules, and then performed standard bacteriocin test
on the same cells. It turned out that LcnB exhibited antimicrobial
effect regardless of the presence of even high concentration
of LcnB∗. This result demonstrated that LcnB∗ is not able to
compete with full-length peptide for the receptor, or in other
words, does not bind components of man-PTS at all.
Taking all the results in consideration, we can conclude that
our newest findings confirm several hypotheses formed in our
previous work. Proteinase PrtP indeed hydrolyzes bacteriocin
LcnB in vivo, but by doing so, inactivates it completely through
destruction of its receptor binding domain. The reason for this,
however, eludes the common microbial logic. There seems to
make no sense for bacteria to destroy their own weapons for
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competition. However, this risk appears merely when PrtP is
excessively expressed, which happens only when bacteria grow
in nitrogen-depleted media, and are in other words starving.
Nevertheless, it should be emphasized that conditions applied in
this study mimicked such situations, and that active bacteriocin
was present in bacterial culture. Hence, this “self-digestion” only
partially jeopardizes host antimicrobial potential, as it seems that
LcnB degradation by PrtP is never so intense to majorly deplete
bacteria of their antimicrobial potential. This is why we consider
that there is physiological explanation for this process. The fate
of generated peptides may be various; for example they may be
involved in signaling or serve as a source of amino acids for the
starving bacterial cells, etc. These are challenging presumptions,
and future research will be driven to address this issue.
AUTHOR CONTRIBUTIONS
GV, NP, NM, and NS contributed to acquisition and analysis of
data. GV, BJ, MK, and DF contributed to design of the work,
analysis, and interpretation of the data. GV, NP, and BJ drafted
the manuscript. MK contributed to the conception of the work
and critically revised the final version to be published.
FUNDING
This work was supported by the Ministry of Education
and Science of the Republic of Serbia, (Grant Nos.
173019 and 173026).
ACKNOWLEDGMENTS
Preprint version of this manuscript was published on BioRxiv
(Vukotic et al., 2018).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2019.00874/full#supplementary-material
FIGURE S1 | Production of LcnB and LcnB∗ by recombinant DNA technology.
(A) PCR amplification of lcnB (1, 2) and its truncated form (3, 4); 5, Generuler DNA
Ladder Mix. (B) NcoI/SacI digestion of cloned PCR products in pMAL-c5X: 1–2,
construct pMAL-c5XI (carrying lcnB); 5–6, construct pMAL-c5XII (carrying
truncated form of lcnB); 3 and 7, empty vector; 4, Generuler DNA Ladder Mix.
Note – the 90 bp increases in size compared to PCR amplicons is derived from
vector. (C) SDS-PAGE of overexpressed clones in E. coli ER2532: 1 and 3, fusions
with MBP; 2 and 4, arrows pointing to proteins of interest (LcnB and LcnB∗,
respectively) released from MBP by Xa protease; 5 spectra multicolor
broad range ladder.
FIGURE S2 | Glucose-uptake inhibition assay. Growth of BGMN1-596 was
monitored in GM17 enriched with different concentrations of LcnB∗. Each line
represents growth with corresponding concentration of LcnB∗, noted in the
picture. Bacteria were also grown in absence of glucose (M17). Bacterial inoculum
was 5% from fresh overnight culture.
FIGURE S3 | Bacteriocin competition assay. Antimicrobial activity of BGMN1-501
was tested on sensitive cells pretreated 30 min with different concentrations of
LcnB∗: (1) negative control BGMN1-596; (2–6) pretreatment done with 1,000;
500; 250; 125, and 62.5 µg/mL of LcnB∗, respectively, (7) pretreatment done with
10 mmol/L NaPi buffer (pH 7) used to dissolve LcnB∗.
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